IGF-1R/IR Receptor Tyrosine Kinase Inhibitors (RTKi): Small molecule inhibitors that target receptor tyrosine kinase activity of the IGF-1R (RTKi) have also been developed for use in breast cancer. This evidence concerns the gene IGF1R and breast carcinoma.